
## **Robert Sloane**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4362195/publications.pdf Version: 2024-02-01



ROBERT SLOANE

#	Article	IF	CITATIONS
1	Multi-modal molecular programs regulate melanoma cell state. Nature Communications, 2022, 13, .	12.8	9
2	ldentification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers, 2021, 13, 5301.	3.7	7
3	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i> -mutated melanoma. Oncolmmunology, 2021, 10, 1992880.	4.6	7
4	Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science, 2018, 359, 97-103.	12.6	3,126
5	The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 5153-5164.	7.0	126
6	Interaction of molecular alterations with immune response in melanoma. Cancer, 2017, 123, 2130-2142.	4.1	24
7	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. Npj Genomic Medicine, 2017, 2, .	3.8	120
8	AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies. Investigational New Drugs, 2015, 33, 679-690.	2.6	43
9	437 PIM kinase inhibitor AZD1208 sensitises SCLC to BH3 mimetic AZD4320. European Journal of Cancer, 2014, 50, 144.	2.8	0
10	Circulating biomarkers in hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2014, 74, 323-332.	2.3	56
11	Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells. BMC Cancer, 2014, 14, 226.	2.6	13
12	Method validation of circulating tumour cell enumeration at low cell counts. BMC Cancer, 2013, 13, 415.	2.6	20
13	Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches. Journal of Thoracic Oncology, 2012, 7, 306-315.	1.1	411
14	Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 525-532.	1.6	755
15	A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. British Journal of Cancer, 2012, 106, 508-516.	6.4	233
16	Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2011, 29, 1556-1563.	1.6	788
17	Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer. American Journal of Pathology, 2011, 178, 989-996.	3.8	386
18	Circulating Tumor Cells, Enumeration and Beyond. Cancers, 2010, 2, 1236-1250.	3.7	42